ANAFRANIL

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Finland, France, Germany, Hong Kong SAR China, Ireland, Israel, Japan, Lithuania, Malta, Mexico, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey.

Active ingredients

The drug ANAFRANIL contains one active pharmaceutical ingredient (API):

1	Clomipramine UNII 2LXW0L6GWJ - CLOMIPRAMINE HYDROCHLORIDE
	The therapeutic activity of clomipramine is believed to be based on its ability to inhibit the neuronal re-uptake of noradrenaline (NA) and serotonin (5-HT) released in the synaptic cleft, with inhibition of 5-HT reuptake being the more important of these activities.
	Read more about Clomipramine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ANAFRANIL Prolonged-release, film-coated tablet	MPI, EU: SmPC	Health Products Regulatory Authority (IE)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N06AA04	Clomipramine	N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AA Non-selective monoamine reuptake inhibitors
Discover more medicines within N06AA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	1561E
BR	Câmara de Regulação do Mercado de Medicamentos	526500902114311, 526501001110314, 526517040088403, 526517040088503
CA	Health Products and Food Branch	00324019, 00330566, 00402591
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	04954736, 04954742, 07152753, 07152776, 07152782, 07356970, 07356987, 07448896, 07478354, 11024860, 16847655
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	24.785-10-02
EE	Ravimiamet	1001462, 1011407, 1011418, 1636073
ES	Centro de información online de medicamentos de la AEMPS	44656, 44657, 49656, 57568
FI	Lääkealan turvallisuus- ja kehittämiskeskus	074192, 102503, 476462
FR	Base de données publique des médicaments	61426025, 69235342, 69273510, 69281119
HK	Department of Health Drug Office	45537, 45562
IE	Health Products Regulatory Authority	14389
IL	מִשְׂרַד הַבְּרִיאוּת	3534, 516
JP	医薬品医療機器総合機構	1174002F1029, 1174002F2025
LT	Valstybinė vaistų kontrolės tarnyba	1000126
MT	Medicines Authority	MA1423/00101, MA1423/00102, MA1423/00103, PI1438/11101A, PI1438/11102A, PI908/02601C, PI908/02602C
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	69402, 84M83
PL	Rejestru Produktów Leczniczych	100005632, 100005649, 100005655
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67624001, W67625001
SG	Health Sciences Authority	07533P
TN	Direction de la Pharmacie et du Médicament	17543011, 17543012, 17543013, 17543014
TR	İlaç ve Tıbbi Cihaz Kurumu	8699529030036, 8699529120010, 8699529120027
US	FDA, National Drug Code	0406-9906, 0406-9907, 0406-9908
ZA	Health Products Regulatory Authority	C/1.2/182, W/1.2/140